Costs Avoided by the Inclusion of Finerenone Based on Hospitalization and Death Due to Cardiovascular Events and the Progression of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D) in Colombia
Author(s)
Claudia A. López-Cabra, MSc, Médica epidemióloga1, Ángela Daniela Rodríguez, MSc, Economist2, wilson Mayorga Mogollon, MSc, Economist2, Diana Smith Lopez, MSc, Economist2, Silvia Juliana Rey, Esp., Médica1, Laura Idrobo, Esp., Médica1, DIANA C. ACOSTA, Esp., Médica1, Diana Gutierrez, MD, Market Access1, Ruben D. Marrugo, MSc, Economist1;
1Bayer, Bogotá, Colombia, 2Numeris, Bogotá, Colombia
1Bayer, Bogotá, Colombia, 2Numeris, Bogotá, Colombia
OBJECTIVES: To estimate the costs avoided from a social perspective by the inclusion of Finerenone including costs from hospitalization and death due to cardiovascular event and progression of CKD
METHODS: Two strategies were evaluated: standard treatment (i.e., ACEi or ARBs) versus standard treatment plus Finerenone, using a Markov model associated to the stages of disease progression. To estimate the effect of including Finerenone on reduction of hospitalization due to cardiovascular events, the FIDELITY study was used, in which the following Hazard Ratios were observed: 0,78 for hospitalization for heart failure. 0,91 for non-fatal myocardial infarction, 0,99 for non-fatal stroke and 0,88 for death from cardiovascular causes. Hospitalization probabilities were calculated for each stage of renal disease and adjusted for Finerenone. Then, hospitalization costs were weighted with these probabilities. Also, we used the outcome for renal outcomes from FIDELITY study. An annual cost for Finerenone of USD$634 per patient/year was considered. Using a Markov model, costs and Disability-Adjusted Life Years (DALYs) were simulated for each strategy and stage of disease, with a transition matrix for a cohort of 1.000 patients aged 40 with T2D
RESULTS: Using an exchange rate of COP$4.061 Colombian pesos per US dollar (USD), the economic burden of CKD and T2D at 2024 prices for every 1.000 people with T2D was USD$105.582 thousand dollars. Including Finerenone in micro and macroalbuminuria stages reduces 19,5% the costs of procedures, medications, and supplies (mainly for dialysis), 5,8% hospitalization costs for cardiovascular risk, 15,3% out-of-pocket expenses, and 8,8% productivity loss, equivalent to 0,92 DALYs per person/year. With the inclusion of Finerenone, total economic burden is USD$100.812 thousand dollars
CONCLUSIONS: The inclusion of Finerenone reduces the economic burden of Diabetic Kidney Disease (DKD) by 4,5%, equivalent to USD$4.770 per patient in time horizon of 37 years
METHODS: Two strategies were evaluated: standard treatment (i.e., ACEi or ARBs) versus standard treatment plus Finerenone, using a Markov model associated to the stages of disease progression. To estimate the effect of including Finerenone on reduction of hospitalization due to cardiovascular events, the FIDELITY study was used, in which the following Hazard Ratios were observed: 0,78 for hospitalization for heart failure. 0,91 for non-fatal myocardial infarction, 0,99 for non-fatal stroke and 0,88 for death from cardiovascular causes. Hospitalization probabilities were calculated for each stage of renal disease and adjusted for Finerenone. Then, hospitalization costs were weighted with these probabilities. Also, we used the outcome for renal outcomes from FIDELITY study. An annual cost for Finerenone of USD$634 per patient/year was considered. Using a Markov model, costs and Disability-Adjusted Life Years (DALYs) were simulated for each strategy and stage of disease, with a transition matrix for a cohort of 1.000 patients aged 40 with T2D
RESULTS: Using an exchange rate of COP$4.061 Colombian pesos per US dollar (USD), the economic burden of CKD and T2D at 2024 prices for every 1.000 people with T2D was USD$105.582 thousand dollars. Including Finerenone in micro and macroalbuminuria stages reduces 19,5% the costs of procedures, medications, and supplies (mainly for dialysis), 5,8% hospitalization costs for cardiovascular risk, 15,3% out-of-pocket expenses, and 8,8% productivity loss, equivalent to 0,92 DALYs per person/year. With the inclusion of Finerenone, total economic burden is USD$100.812 thousand dollars
CONCLUSIONS: The inclusion of Finerenone reduces the economic burden of Diabetic Kidney Disease (DKD) by 4,5%, equivalent to USD$4.770 per patient in time horizon of 37 years
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE443
Topic
Economic Evaluation
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Urinary/Kidney Disorders